Abstract Number: 1265 • 2012 ACR/ARHP Annual Meeting
Lipoprotein Subclass Particles and Small Vessel Elasticity As a Potential Marker for Early Atherosclerosis in Rheumatoid Arthritis: a Prospective, Controlled Study
Background/Purpose: Rheumatoid arthritis (RA) has increased rates of cardiovascular (CV) events. However, standard CV risk factors, such as routine lipid profiles, are not different in…Abstract Number: 640 • 2012 ACR/ARHP Annual Meeting
Association of Body Weight with Cardiovascular Events in Systemic Lupus Erythematosus
Background/Purpose: Excessive body mass among healthy subjects carries an increased risk of subsequent cardiovascular (CV) events. In healthy subjects, the relationship between body mass index…Abstract Number: 2180 • 2012 ACR/ARHP Annual Meeting
Coronary Flow Reserve and Asymmetric Dimethylarginine Levels: New Measurements for Identifying Subclinical Atherosclerosis in Patients with Primary Sjögren’s Syndrome
Background/Purpose: Clinical and biochemical data suggest that autoimmune diseases are associated with endothelial dysfunction and increased atherosclerosis. We have previously shown that asymmetric dimethylarginine (ADMA)…Abstract Number: 1267 • 2012 ACR/ARHP Annual Meeting
Inflammatory Burden Predicts Progression of Carotid Plaque in Rheumatoid Arthritis: A 24-Month Longitudinal Analysis
Background/Purpose: Carotid atherosclerosis, which is associated with the increased risk of cardiovascular (CV) disease, is increased in rheumatoid arthritis (RA) patients. In our previous study,…Abstract Number: 623 • 2012 ACR/ARHP Annual Meeting
Endothelial Microparticles As a Biomarker for Endothelial Dysfunction in Active Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with an increased risk of clinical and subclinical cardiovascular disease (CVD) including endothelial dysfunction, in part due to…Abstract Number: 2157 • 2012 ACR/ARHP Annual Meeting
Resveratrol Counters Pro-Atherogenic Effects of Systemic Lupus Erythematosus and Rheumatoid Arthritis Plasma On Cholesterol Efflux in Human Macrophages
Background/Purpose: Our group has demonstrated that resveratrol, a plant polyphenol, possesses atheroprotective properties, enhancing expression of reverse cholesterol transport (RCT) proteins. We have reported that Systemic…Abstract Number: 1268 • 2012 ACR/ARHP Annual Meeting
Lipid Alterations and Measurement of Arterial Stiffness in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Increased arterial stiffness, an independent risk factor for premature coronary artery disease, has been reported in…Abstract Number: 596 • 2012 ACR/ARHP Annual Meeting
Evolution of Atherosclerosis in Psoriatic Arthritis: Is the Former an Independent Inflammatory Process?
Background/Purpose: A non-invasive study focusing on the structural and functional properties of the carotid arteries was carried out in psoriatic arthritis (PsA) patients. Increased cardiovascular…Abstract Number: 1720 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Risk Management in Rheumatoid Arthritis Is Nurse Led Intervention Effective?
Background/Purpose: There is a recognised increase in the incidence of heart disease in patients with rheumatoid arthritis (RA) Surveys of usual practice however frequently show…Abstract Number: 1243 • 2012 ACR/ARHP Annual Meeting
Effect of Tocilizumab Treatment On Regional Left Ventricular Function, As Assessed by Cardiac Magnetic Resonance Imaging, in Rheumatoid Arthritis Patients without Cardiac Symptoms
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of congestive heart failure, possibly via shared mechanisms of inflammation. This study was undertaken to…Abstract Number: 480 • 2012 ACR/ARHP Annual Meeting
Etanercept Induces A Significant Decrease of Oxidative Stress and Osteoprotegerin Compared with Sdmard in Patients with Rheumatoid Arthritis
Background/Purpose: TNF-inhibitors are known to decrease cardiovascular events in rheumatoid arthritis (RA) as compared with synthetic disease modifying anti-rheumatic drugs (sDMARD). However, mechanisms involved remain…Abstract Number: 1702 • 2012 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Blocking Agents Inhibit the Progression of Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is associated with an increased cardiovascular (CV) risk that might be due to the chronic underlying inflammatory process. It is still…Abstract Number: 1245 • 2012 ACR/ARHP Annual Meeting
Age-Specific Association Between Disease-Related Measures and Incident Cardiovascular Events and All-Cause Mortality in Early Rheumatoid Arthritis
Background/Purpose: Increased risk of cardiovascular disease (CVD) and premature mortality in rheumatoid arthritis (RA) has been established, but the impact of inflammatory and disease related…Abstract Number: 350 • 2012 ACR/ARHP Annual Meeting
Reduction of Inflammation with Abatacept and Tocilizumab Results in Lower N-Terminal Pro Brain Natriuretic Peptide Levels in Patients with Rheumatoid Arthritis: Results From Prospective Cohort Studies
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of heart failure (HF). The chronic inflammatory state in RA is associated with increased levels of…Abstract Number: 1682 • 2012 ACR/ARHP Annual Meeting
Sustained Clinical Remission (Disease Activity Score 28 <2.6) Protects for Cardiovascular Disease in Rheumatoid Arthritis Patients
Background/Purpose: Chronic inflammation appears to be an independent risk factor for CVD in rheumatoid arthritis (RA), but there is no clear difference in CVD risk…
ACR Meeting Abstracts